Osteologix (OLGX) POS AM Prospectus update (post-effective amendment)

As filed with the Securities and Exchange Commission on January 4, 2011

Registration No. 333-150971

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1
TO

FORM S-1

REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

OSTEOLOGIX, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	2834
(State or other jurisdiction of	(Primary Standard Industrial Classification Code Number)
incorporation or organization)
	32-0104570
	(I.R.S. Employer Identification Number)

4415 Cox Road
Glen Allen, VA 23060
Phone: (804) 747-6027
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Philip J. Young
President and Chief Executive Officer
4415 Cox Road
Glen Allen, VA 23060
Phone: (804) 747-6027
(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:
Stephen B. Thau
Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, CA 94304
Phone: (650) 813-5640

APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:Not applicable.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.o

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.o

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.o

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filero	Accelerated filero	Non-accelerated filero	Smaller reporting companyþ
		(Do not check if a smaller reporting company)

DEREGISTRATION OF SECURITIES

On May 16, 2008, Osteologix, Inc. (the “Registrant”) filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-1, Registration No. 333-150971 (the “Registration Statement”), for the sale from time to time by the selling stockholders of up to 1,500,000 shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”), including up to an aggregate of 500,000 shares of the Common Stock issuable upon the exercise of warrants. The Registrant files this Post-Effective Amendment No. 1 to the Registration Statement and hereby deregisters all shares of the Common Stock unissued under the Registration Statement.

2

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Glen Allen, state of Virginia on this 4th day of January 2011.

OSTEOLOGIX, INC.
By:	/s/ Philip J. Young
	Philip J. Young
	President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the date indicated.

Name	Title	Date
/s/ John M. Barberich	Chairman and Director	January 4, 2011
John M. Barberich
/s/ Klaus Eldrup-Jørgensen, M.D.	Director	January 4, 2011
Klaus Eldrup-Jørgensen, M.D.
/s/ Philip J. Young	Chief Executive Officer, Principal Financial	January 4, 2011
Philip J. Young	Officer, Principal Accounting Officer and Director
/s/ Enda Kenny, Ph.D.	Director	January 4, 2011
Enda Kenny, Ph.D.
/s/ David O’Flynn	Director	January 4, 2011
David O’Flynn